Long non‐coding RNA T‐cell factor 7 in multiple myeloma: A potential biomarker for deteriorated clinical features and poor prognosis

Abstract

Background This study aimed to investigate the correlation of long non‐coding RNA T‐cell factor 7 (lnc‐TCF7) with clinical features and prognosis in patients with multiple myeloma (MM). Methods Totally, 216 newly diagnosed symptomatic MM patients and 60 healthy controls (HCs) were enrolled. Bone marrow samples were collected from patients before treatment and from HCs on donation to detect lnc‐TCF7 expression in plasma cells by reverse transcription quantitative polymerase chain reaction. Besides, clinical response, progression‐free survival (PFS), and overall survival (OS) of patients were assessed. Results Lnc‐TCF7 expression was increased in patients with MM compared with HCs. Lnc‐TCF7 expression was highest in international staging system (ISS) stage III patients, followed by ISS stage II patients, and then ISS stage I patients, while lnc‐TCF7 expression was similar in patients with different immunoglobulin subtypes and Durie‐Salmon stages. Regarding chromosomal abnormalities, lnc‐TCF7 expression positively correlated with t(4; 14) and Del(17p), whereas no correlation of lnc‐TCF7 expression with t(14; 16), 1q21 amplification, Del(13q), or hyperdiploid was observed in patients with MM. Furthermore, lnc‐TCF7 expression positively correlated with serum creatinine, beta‐2‐microglobulin, and lactate dehydrogenase in patients. Besides, lnc‐TCF7 was negatively associated with complete response but not overall response rate in patients. Additionally, patients with lnc‐TCF7 high expression exhibited shorter PFS and OS compared to patients with lnc‐TCF7 low expression. Conclusion Lnc‐TCF7 might have clinical value in aiding disease management and prognosis prediction of MM.

RETRACTED: LncRNA TCF7 Promotes Epithelial Ovarian Cancer Viability, Mobility and Stemness via Regulating ITGB8

“…Among previously reported lncRNAs, lncRNA T-cell factor 7 (lnc-TCF7) serves as a vital oncogene, which contributes to malignant behaviors and cancer stemness in several carcinomas, such as non-small cell lung, colorectal and liver cancers (7)(8)(9)(10). Besides, lnc-TCF7 exhibits potency as a prognostic marker reflecting advanced tumor stages and worse survival in some carcinomas (11)(12)(13). However, no previous studies have been performed on the function and mechanism of lnc-TCF7 in EOC, as well as its clinical value for EOC prognosis.…”

The Expression of Serum lncRNA MIR17HG in Patients with Multiple Myeloma and Its Clinical Significance

“…Likewise, our fndings revealed that MM patients with high MIR17HG expression had signifcantly shorter PFS and OS than those with low MIR17HG expression. In light of the fact that MIR17HG is associated with higher Scr, LDH levels, and more advanced clinical stages, which are associated with poorer survival of MM patients [36], it is not difcult to infer that the high MIR17HG expression is associated with adverse survival of MM patients.…”

The Role of lncRNAs in the Pathobiology and Clinical Behavior of Multiple Myeloma

“…The overexpression of the cytoplasmic circular lncRNA Circ_0000190, MEG3 and PRAL has been associated with better PFS and OS, and high expression levels of SMILO (specific myeloma intergenic long non-coding RNA) with better OS in MM patients [ 13 , 36 , 72 , 86 , 87 ]. By contrast, high expression levels of lnc-TCF7 , MALAT1 , MIAT , NEAT1 and PDLIM1P4 have been associated with worse PFS and OS in MM patients [ 13 , 61 , 63 , 70 , 75 , 76 , 77 , 80 ], the overexpression of CRNDE , LINC00152 , LINC00461 , LINC01234 , lnc-ANGPTL1-3 , PDIA3P and UCA1 with worse OS, and the overexpression of ENSG00000254343 , H19 and NR_046683 (also known as ST3GAL6-AS1 , ST3GAL6 antisense RNA 1) with worse PFS in MM patients [ 13 , 40 , 46 , 56 , 85 , 93 , 95 ]. In addition, high expression levels of LUCAT1 were associated with worse five-year survival rates [ 62 ], and MM patients with the lncRNA BM742401 methylated showed worse OS than those patients with unmethylated BM742401 [ 35 ].…”